Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tadalafil vs Tamsulosin in BPH
NCT00970632Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2009
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of tadalafil in benign prostatic hyperplasia (BPH) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: International Prostate Symptom Score at 12 weeks. Started Oct 2009; status: completed.
02
Drugs
tadalafil
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT00970632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00970632.